熱門資訊> 正文
Windtree Therapeutics GAAP每股收益为-20.91美元，落后18.64美元
2024-08-21 04:14
- Windtree Therapeutics press release (NASDAQ:WINT): Q2 GAAP EPS of -$20.91 misses by $18.64.
- As of June 30, 2024, the Company reported cash and cash equivalents of $1.8 million and current liabilities of $8.8 million. We do not have sufficient cash and cash equivalents as of the date of this Quarterly Report on Form 10-Q to support our operations for at least the 12 months following the date that the financial statements are issued. These conditions raise substantial doubt about our ability to continue as a going concern.
More on Windtree Therapeutics
- Seeking Alpha’s Quant Rating on Windtree Therapeutics
- Historical earnings data for Windtree Therapeutics
- Financial information for Windtree Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
